Progesterone Estrogen Steroids Hormones Powder Altrenogest Manufacturer CAS 850-52-2

Altrenogest

Synonym: 11-trien-3-one,17-alpha-allyl-17-hydroxy-estra-9;17-allyltrenbolone;17-alpha-allyl-estratriene-4,9,11,17-beta-ol-3-one;17-hydroxy-17-(2-propenyl)-(17-beta)-estra-11-trien-3-one;drc6246;r2267;ru2267;ALLYLTRENBOLONE
CAS Registry Number: 850-52-2
Assay: 99%
Molecular Formula: C21H26O2
Molecular Weight: 310.43
Appearance: Light yellow crystal or powder
Min order:10g
Payment:T/T,,money gram
Delivery time:4-6 working days

Itis a progestogen structurally related to veterinary steroid trenbolone.

Altrenogest is a synthetic trienic C21 steroidal progestomimetic, belonging to the 19-nor-testosterone series. It is an orally active (pro)gestagen. Like all steroids, altrenogest acts by its liposolubility by penetrating the target cells where it binds to specific receptors. In veterinary medicine, altrenogest is used in gilts and mares for zootechnical purposes (oestrus synchronization).

Target: Progesterone Receptor

Altrenogest is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with altrenogest appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. Altrenogest treatment also seems to be conductive to pregnancy maintenance in recipients experiencing luteal dysfunction [1]. The oil and gel altrenogest preparations are equally effective in modulating estrous behavior and time to estrus and ovulation.

Altrenogest treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.

Use:

Altrenogest is indicated (labeled) to suppress estrus in mares to allow a more predictable occurrence of estrus following withdrawal of the drug. It is used clinically to assist mares to establish normal cycles during the transitional period from anestrus to the normal breeding season often in conjunction with an artificial photoperiod. It is more effective in assisting in pregnancy attainment later in the transition period. One group of authors (Squires et al. 1983) suggest selecting mares with considerable follicular activity (mares with one or more follicles 20 mm or greater in size) for treatment during the transitional phase. Mares that have been in estrus for 10 days or more and have active ovaries are also considered to be excellent candidates for progestin treatment.

Altrenogest is effective in normally cycling mares for minimizing the necessity for estrus detection, for the synchronization of estrus and permitting scheduled breeding. Estrus will ensue 2-5 days after treatment is completed and most mares ovulate between 8-15 days after withdrawal. Altrenogest is also effective in suppressing estrus expression in show mares or mares to be raced. Although the drug is labeled as contraindicated during pregnancy, it has been demonstrated to maintain pregnancy in oophorectomized mares and may be of benefit in mares who abort due to sub-therapeutic progestin levels.